List of Excipients in Branded Drug TROSPIUM CHLORIDE ER

« Back to Dashboard

Generic Drugs Containing TROSPIUM CHLORIDE ER

Company	Ingredient	NDC	Excipient
35573	trospium chloride er	35573-446	AMMONIA
35573	trospium chloride er	35573-446	ETHYLCELLULOSE
35573	trospium chloride er	35573-446	FD&C BLUE NO. 1
35573	trospium chloride er	35573-446	FD&C RED NO. 40
35573	trospium chloride er	35573-446	FD&C YELLOW NO. 6
35573	trospium chloride er	35573-446	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in TROSPIUM CHLORIDE ER?

# Of NDCs	Excipient
1	AMMONIA
1	ETHYLCELLULOSE
1	FD&C BLUE NO. 1
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6
1	FERROSOFERRIC OXIDE

Trospium Chloride ER Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Trospium chloride extended-release, marketed as Sanctura XR, is a once-daily 60 mg oral capsule for overactive bladder. The main commercial opportunity is a differentiated generic or reformulated extended-release product that preserves 24-hour exposure while improving manufacturability, food-effect control, capsule robustness, supply reliability, or patient use. The principal technical risks are dissolution drift, dose dumping, food sensitivity, moisture exposure, and bioequivalence failure.

What is the commercial profile of trospium chloride ER?

Trospium chloride is a quaternary ammonium antimuscarinic. Its permanent positive charge limits gastrointestinal and central nervous system penetration relative to many tertiary amine anticholinergics. Sanctura XR is administered once daily, while immediate-release trospium chloride is generally administered twice daily on an empty stomach. The extended-release product therefore competes on dosing convenience and exposure management.

Attribute	Trospium chloride ER
Reference product	Sanctura XR
Active ingredient	Trospium chloride
Strength	60 mg
Dosage form	Extended-release capsule
Administration	Once daily
Therapeutic category	Antimuscarinic for overactive bladder
Regulatory pathway for copies	ANDA, subject to FDA product-specific requirements
Key performance target	Comparable extended-release exposure and dissolution
Main commercial customers	Generic pharmacies, managed-care plans, wholesalers, urology practices

The product is an oral small-molecule drug, not a biologic. Biosimilar competition is therefore not relevant. Competition will arise primarily from ANDA-approved generics, authorized-generic arrangements, therapeutic substitutes, and alternative overactive-bladder medicines.

What excipient strategy is appropriate for trospium chloride ER?

A multiparticulate capsule strategy is generally attractive because it can separate drug release from capsule disintegration and provide control over the release profile through particle coating. A monolithic matrix capsule or tablet may offer lower manufacturing cost, but it can create greater sensitivity to compression, polymer hydration, particle size, and food-related gastrointestinal transit.

Multiparticulate bead strategy

A bead-based formulation can use:

• An inert starter core or drug-loaded pellet.
• A binder such as povidone or a cellulosic polymer.
• A release-controlling coating based on aqueous or organic polymer technology.
• Anti-tacking agents such as talc or colloidal silicon dioxide.
• A hard gelatin or hypromellose capsule shell.
• A capsule fill blend engineered for uniformity and low segregation.

The principal advantage is tunability. Release can be adjusted through coating weight gain, polymer ratio, pore-former content, plasticizer level, pellet diameter, and curing conditions. Multiparticulates also reduce the risk that one damaged unit will release the entire dose.

Matrix strategy

A hydrophilic matrix can use hydroxypropyl methylcellulose or a related release-controlling polymer. The approach may lower process complexity, but the manufacturer must control:

• Polymer viscosity grade.
• Drug-to-polymer ratio.
• Granule porosity.
• Compression force or fill density.
• Water penetration and gel-layer formation.
• Food-induced changes in gastrointestinal residence time.

For a capsule product, a multiparticulate matrix fill can combine the manufacturing simplicity of a powder or granule with the release control of a polymer matrix.

Capsule-shell strategy

The capsule shell should be evaluated as part of the formulation rather than treated as packaging. Key variables include:

• Gelatin versus hypromellose shell.
• Shell moisture content.
• Brittleness at low relative humidity.
• Cross-linking during storage.
• Compatibility with the fill blend.
• Opacity and light protection.
• Printing ink extractables and leachables.

A hypromellose shell may offer a differentiated supply option for vegetarian markets and may reduce certain gelatin-related supply constraints. It can also change moisture transfer and dissolution behavior. Any shell change requires comparative dissolution, stability, and likely bioequivalence assessment.

Which excipients are most commercially valuable?

The highest-value excipient decisions are those that improve process capability without changing the clinical release profile.

Excipient function	Candidate classes	Commercial purpose
Binder	Povidone, hydroxypropyl cellulose	Improves drug-layer adhesion and granule strength
Release control	Hypromellose, ethylcellulose, methacrylate copolymers	Controls 24-hour drug release
Matrix former	High- or low-viscosity hypromellose	Supports simpler ER architecture
Anti-tacking agent	Talc, colloidal silicon dioxide	Improves coating throughput
Lubricant	Magnesium stearate or equivalent	Supports capsule filling and powder flow
Disintegrant	Crospovidone, croscarmellose sodium	Controls pellet or matrix rupture where needed
Plasticizer	Triethyl citrate, polyethylene glycol	Improves coating flexibility
Pore former	Water-soluble polymer or sugar	Fine-tunes release and lag time
Capsule shell	Gelatin or hypromellose	Provides dosage-form protection and market differentiation

Trospium chloride’s ionic character creates formulation opportunities but also raises compatibility questions. The manufacturer should screen excipients for ionic interactions, adsorption, pH effects, hygroscopicity, and changes in apparent solubility. Excipients with strong anionic functionality may be particularly important to evaluate because ion pairing or local microenvironment effects could alter drug release.

What formulation patents protect trospium chloride ER?

The relevant intellectual-property assessment should separate the active ingredient from the extended-release dosage form.

Trospium chloride as a chemical entity has a much older patent history than the once-daily extended-release product. The remaining commercial barriers, if any, are more likely to involve dosage-form design, release-control architecture, manufacturing processes, or product-specific regulatory protections than basic compound claims.

A generic sponsor should review:

1. U.S. patents listed for the reference product in the FDA Orange Book.
2. Patent family members covering extended-release capsules, beads, pellets, or coating systems.
3. Continuation and divisional applications.
4. Patent term adjustment and patent term extension records.
5. Paragraph IV litigation and settlement activity.
6. Foreign equivalents in Europe, Canada, Japan, and other target markets.
7. Freedom-to-operate issues involving proprietary coating processes or capsule-fill technologies.

The FDA Orange Book remains the controlling source for patents and exclusivity associated with approved listed drugs. Patent status should be checked at the time of filing because listings and litigation positions can change. [1]

When does trospium chloride ER lose exclusivity?

Sanctura XR’s commercial exclusivity is no longer the primary barrier to generic development. Trospium chloride is an established small molecule, and the relevant U.S. regulatory route is an ANDA rather than a 505(b)(2) application for a substantially equivalent product.

The launch analysis must still distinguish:

• FDA regulatory exclusivity.
• Listed patent expiration.
• Unexpired formulation or process patents.
• Pediatric exclusivity.
• Litigation-based launch restrictions.
• Commercial supply arrangements.
• State substitution and payer-formulary timing.

FDA approval does not automatically eliminate patent risk. An ANDA sponsor must certify to Orange Book patents, including a Paragraph IV certification when it seeks approval before listed patent expiration. [1,2]

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV strategy is most relevant when a generic sponsor believes listed patents are invalid, unenforceable, or not infringed. The sponsor must provide notice to the patent owner and NDA holder. The patent owner may file an infringement action within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework. [2]

For trospium chloride ER, the principal litigation questions would likely concern:

• Whether the proposed dissolution profile falls within a formulation claim.
• Whether a different coating polymer avoids literal infringement.
• Whether a bead-size or coating-weight limitation is met.
• Whether a process claim reaches the generic manufacturing route.
• Whether patent claims are enabled and adequately described.
• Whether the generic product is therapeutically equivalent despite a different excipient system.

A non-infringing formulation can be commercially preferable to a Paragraph IV challenge if the formulation can achieve acceptable bioequivalence without relying on the disputed patent architecture.

How strong is the patent estate for trospium chloride ER?

The patent estate is likely weaker at the active-ingredient level than at the dosage-form level because trospium chloride is an established compound. Strength depends on the breadth and remaining term of formulation claims, not on the age of the molecule alone.

Patent-risk factor	Assessment
Compound patent risk	Low relative to newer branded drugs
ER formulation risk	Potentially material
Process patent risk	Dependent on coating and pellet technology
Regulatory exclusivity risk	Limited for an established product
Design-around potential	Moderate to high if claims are narrow
Bioequivalence risk	Material
Manufacturing barrier	Moderate, particularly for multiparticulates
Biosimilar risk	None

The strongest generic position generally combines a non-infringing formulation with a dissolution profile that matches the reference product across multiple media and agitation conditions.

What FDA regulatory issues affect a trospium chloride ER generic?

The generic sponsor must demonstrate pharmaceutical equivalence and bioequivalence. For an extended-release product, a single fasting study may not adequately de-risk development. Fed studies, multiple-dose studies, partial AUC measurements, and alcohol-dose-dumping evaluations may be relevant depending on FDA product-specific guidance and the proposed formulation.

Critical CMC packages should address:

• Assay and content uniformity.
• Drug loading across multiparticulate units.
• Release profile under discriminatory dissolution conditions.
• Stability at long-term and accelerated conditions.
• Capsule-shell interaction.
• Moisture uptake.
• Residual solvents from coating.
• Microbial controls for aqueous coating systems.
• Alcohol-induced release acceleration.
• Scale-up effects on coating uniformity.

FDA’s modified-release guidance emphasizes control of formulation variables and in vitro dissolution because dissolution behavior can affect in vivo exposure. [3]

What commercial opportunities exist for excipient innovation?

Low-cost generic substitution

The most direct opportunity is an ANDA product using widely available excipients and a robust manufacturing process. A low-cost formulation should avoid dependence on a single specialty polymer supplier and should tolerate normal variation in coating weight, particle size, and capsule moisture.

Hypromellose capsule differentiation

A hypromellose shell could support vegetarian positioning and supply-chain diversification. The commercial value is limited if payers treat the product as interchangeable, but it may help institutional customers with formulation or procurement requirements.

Improved food-effect performance

A formulation with reduced fed-versus-fasted variability could support a clearer administration message. This is commercially meaningful because immediate-release trospium products are associated with empty-stomach administration requirements. Any claim of improved food tolerance would require regulatory support and must not be inferred from in vitro testing alone.

Supply-chain resilience

Excipient substitution creates value when it reduces exposure to shortages, single-source polymers, or specialized coating materials. A dual-source strategy should be designed during development because post-approval changes may require regulatory supplements and additional comparability work.

Private-label and regional licensing

Trospium chloride ER is suitable for licensing to generic companies with established urology portfolios. Potential structures include:

• Technology licensing for a non-infringing ER platform.
• Regional commercialization rights.
• Contract development and manufacturing.
• Authorized-generic supply.
• Co-development with a finished-dose manufacturer.
• Portfolio bundling with immediate-release trospium or other urology products.

The strongest licensing asset would be a validated formulation with demonstrated bioequivalence, scalable coating capability, and freedom-to-operate analysis.

How does trospium chloride ER compare with competing overactive-bladder drugs?

Product category	Dosing profile	Formulation opportunity	Competitive issue
Trospium IR	Typically twice daily	Conventional immediate-release tablet	Empty-stomach administration
Trospium ER	Once daily	Beads, matrix, or coated multiparticulates	Generic substitution and ER bioequivalence
Oxybutynin ER	Once daily	Matrix or osmotic technologies	Larger established generic market
Solifenacin	Once daily	Immediate-release tablet	Competes on convenience and tolerability
Darifenacin ER	Once daily	Controlled-release tablet	Smaller commercial segment
Mirabegron	Once daily	Extended-release tablet	Different mechanism and safety profile

Trospium ER’s main differentiator is the combination of once-daily dosing and an antimuscarinic mechanism with limited central penetration. Its market position remains exposed to generic competition from other antimuscarinics and to beta-3 agonists such as mirabegron.

What generic launch scenarios exist?

Scenario 1: Conventional generic launch

A sponsor develops a formulation close to the reference product, files an ANDA, and competes primarily on price. This is the lowest differentiation strategy but may have the shortest development path.

Scenario 2: Design-around formulation

A sponsor uses a different release-control polymer, shell, or particle architecture to reduce patent exposure. The benefit is stronger freedom to operate. The cost is higher development and bioequivalence risk.

Scenario 3: Regional or private-label launch

A manufacturer supplies a partner with an approved product or finished-dose capacity. This reduces commercial overhead but may compress margins.

Scenario 4: Formulation-led premium generic

A sponsor pursues a meaningful delivery advantage, such as improved food-effect performance or a differentiated capsule shell. This strategy has greater regulatory and clinical risk and may not receive a premium in a substitution-driven market.

What revenue exposure should investors and licensors assess?

Revenue exposure depends on the reference product’s net sales, generic penetration, channel mix, and therapeutic substitution. The critical variables are:

• Number of approved ANDA competitors.
• Timing of first generic entry.
• Presence of authorized generic supply.
• Reimbursement tier placement.
• Wholesale acquisition price.
• Gross-to-net discounts.
• Manufacturing yield and coating capacity.
• Litigation settlement restrictions.
• Ability to supply multiple strengths or related products.

For a mature product, manufacturing cost and supply reliability usually matter more than brand-level price premiums. A formulation that lowers batch failure, coating variability, or excipient dependence may generate more durable value than a cosmetic excipient change.

Key Takeaways

• Trospium chloride ER is a small-molecule, once-daily extended-release capsule with no biosimilar pathway.
• The strongest formulation opportunity is a robust multiparticulate or matrix system that maintains 24-hour release and limits food-effect variability.
• Excipient selection should prioritize release control, ionic compatibility, moisture management, capsule integrity, and supply resilience.
• The main intellectual-property risk is likely to reside in extended-release formulation and manufacturing claims rather than the old active-ingredient claims.
• Generic sponsors should evaluate Paragraph IV exposure, Orange Book listings, dissolution similarity, alcohol dose dumping, and capsule-shell effects.
• Commercial value is highest for a low-cost, scalable, non-infringing product with reliable supply and validated bioequivalence.

FAQs

Is trospium chloride ER eligible for an ANDA?

Yes. A therapeutically equivalent copy of the approved extended-release product would generally use the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, and patent certifications.

Which excipient is best for extending trospium chloride release?

No single excipient is universally best. Hypromellose, ethylcellulose, and methacrylate polymers can support extended release, but the optimal choice depends on drug loading, particle architecture, dissolution targets, food effect, and manufacturing equipment.

Can a generic use a different capsule shell from Sanctura XR?

Potentially. A generic may use a different gelatin or hypromellose capsule if the product meets pharmaceutical-equivalence, stability, dissolution, bioequivalence, and labeling requirements. The shell change must not create a meaningful performance difference.

Does trospium chloride ER have biosimilar competition?

No. Trospium chloride is a chemically synthesized small molecule. Competition occurs through generic drug approval, not biosimilar approval.

Is a Paragraph IV challenge necessary to launch a trospium chloride ER generic?

No. A sponsor may use other certification strategies or wait for relevant patent expiration. A Paragraph IV certification is a strategic choice when the sponsor seeks approval before expiration of a listed patent and asserts that the patent is invalid, unenforceable, or not infringed.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2017). The ANDA submission: Content, format, and labeling. FDA.

3. U.S. Food and Drug Administration. (1997). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.

4. U.S. Food and Drug Administration. (n.d.). Sanctura XR: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.